Emerging Roles of SIRT1 in Cancer Drug Resistance
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Innate resistance to various therapeutic interventions is a hallmark of cancer. In recent years, acquired resistance has emerged as a daunting challenge to targeted cancer therapy, which abolishes the efficacy of otherwise successful targeting drugs. Cancer cells gain the resistance property through a variety of mechanisms in primary and metastatic cancers, involving cellular intrinsic and extrinsic factors. Increasing evidence suggests that the mammalian stress response gene sirtuin 1 (SIRT1) plays a critical role in multiple aspects of cancer drug resistance. SIRT1 decreases drug penetration, confers proliferation and antiapoptotic survival advantages to cancer cells, facilitates acquired resistance through genetic mutations, promotes the survival of cancer stem cells, and changes the tumor microenvironment for resistance in cell-autonomous and -nonautonomous manners. This article provides an overview of research advances in the roles of SIRT1 in cancer drug resistance and highlights the prospect of targeting SIRT1 as a new strategy to overcome cancer drug resistance and improve therapeutic outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 2×
“Traditionally, innate resistance is known to be mediated by several mechanisms including 1) reduced drug intake through mutations or loss of drug transporters, enhanced drug efflux by overexpressing ATPbinding cassette (ABC) transporters such as ABCB1 (also known as multidrug resistance protein 1 [MDR1]) and multidrug…”
BackgroundPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“Although the development of BCR-ABL tyrosine kinase inhibitor (TKI) imatinib mesylate significantly advances CML treatment,(83) acquired resistance primarily mediated by genetic mutations of BCR-ABL remains a challenge, in particular, for the advanced phases of the disease.(68,69,84) Mutations of BCR-ABL change the co…”
BackgroundDrug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“With transcriptional reprogramming during the EMT process, cancer cells could change their phenotypic display as a result of partial dedifferentiation and acquire CSC properties, resulting in drug resistance.(101) SIRT1 is found to be a positive regulator of EMT.”
BackgroundNegative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Sirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008 · cited 1×
“The nonhistone substrates of SIRT1 account for many biological functions that SIRT1 regulates, and they include numerous molecules in various species: 1) the transcriptional factors p53, FOXO1, FOXO3a, NF-κB, c-Myc, N-Myc, E2F, PTEN, HIF-1α/ HIF-2α, PPARγ, and PGC1α; 2) histonemodifying enzymes SUV39H1, p300, TIP60, a…”
BackgroundEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Lin, S.-J., Defossez, P.-A., & Guarente, L. (2000) · Science · doi:10.1126/science.289.5487.2126 · Cited by 1,775 · cited 1×
“There are 7 sirtuin family members, and among them, SIRT1 has the highest homology to the founding member of NAD-dependent lysine deacetylases, yeast silent information regulator 2 (Sir2), that is associated with life-span extension upon calorie restriction.(11) Extensive studies over the past decade have established…”
BackgroundTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress
Kops, G. J. P. L., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W. A., Coffer, P. J., Huang, T.-T., Bos, J. L., Medema, R. H., & Burgering, B. M. T. (2002) · Nature · doi:10.1038/nature01036 · Cited by 1,580 · cited 1×
“For example, SIRT1 activates FOXO3a and increases the expression of manganese SOD (MnSOD) mRNA and protein, which contributes to cellular resistance to oxidative stress.(48,49) Similarly, activation of SIRT1 in breast cancer cells activates SOD and glutathione peroxidase (Gpx) against oxidative stress.”
BackgroundGranulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485 · cited 1×
“CSCs may arise from self-renewing stem cells by the acquisition of mutations or from more differentiated cells after the gain of function of CSC properties.(94,95) CSCs are essential for cancer development and can serve as the source of primary cancer or a reservoir of cells with the capability of relapse or metastasi…”
BackgroundSIRT1 regulates circadian clock gene expression through PER2 deacetylation
Asher, G., Gatfield, D., Stratmann, M., Reinke, H., Dibner, C., Kreppel, F., Mostoslavsky, R., Alt, F. W., & Schibler, U. (2008) · Cell · doi:10.1016/j.cell.2008.06.050 · Cited by 1,376
The role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Circadian Control of the NAD + Salvage Pathway by CLOCK-SIRT1
Nakahata, Y., Sahar, S., Astarita, G., Kaluzova, M., & Sassone-Corsi, P. (2009) · Science · doi:10.1126/science.1170803 · Cited by 1,198
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205670200 · Cited by 1,002 · cited 3×
“Deleted in breast cancer 1 (DBC1) suppresses SIRT1 activity by binding to the SIRT1 catalytic core,36 in competition with the SIRT1 C-terminal intramolecular “on-switch” peptide that activates the deacetylase function.37 Active regulator of SIRT1 (AROS) positively regulates SIRT1 activity through direct interaction wi…”
BackgroundInfluentialThe silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases
Landry, J., Sutton, A., Tafrov, S. T., Heller, R. C., Stebbins, J., Pillus, L., & Sternglanz, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.110148297 · Cited by 970
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin.
Vaquero, A., Scher, M., Lee, D., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.031 · Cited by 916
Mattagajasingh, I., Kim, C.-S., Naqvi, A., Yamamori, T., Hoffman, T. A., Jung, S.-B., DeRicco, J., Kasuno, K., & Irani, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704329104 · Cited by 881
SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging
Oberdoerffer, P., Michan, S., McVay, M., Mostoslavsky, R., Vann, J., Park, S.-K., Hartlerode, A., Stegmuller, J., Hafner, A., Loerch, P., et al. (2008) · Cell · doi:10.1016/j.cell.2008.10.025 · Cited by 852
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793
SIRT1 Improves Insulin Sensitivity under Insulin-Resistant Conditions by Repressing PTP1B
Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X., & Zhai, Q. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.08.014 · Cited by 766
Sirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible Factor 1α
Lim, J.-H., Lee, Y.-M., Chun, Y.-S., Chen, J., Kim, J.-E., & Park, J.-W. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.023 · Cited by 758 · cited 2×
“In addition, it has been reported that SIRT1 helps cells survive against a hypoxic environment by activating hypoxia-inducible transcription factors HIF2α while contrastingly inactivating HIF1α.(112,113) More studies are needed to further clarify and understand how SIRT1 regulates the tumor microenvironment for drug r…”
BackgroundSirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer
Herranz, D., Muñoz-Martin, M., Cañamero, M., Mulero, F., Martinez-Pastor, B., Fernandez-Capetillo, O., & Serrano, M. (2010) · Nature Communications · doi:10.1038/ncomms1001 · Cited by 612 · cited 1×
“The tumor suppressor role of SIRT1 is illustrated in several mouse studies demonstrating that SIRT1 overexpression reduces colon and intestinal polyps in APC mice,(114) thymic lymphoma in p53 mice,(59) and spontaneous carcinoma/sarcoma or carcinogen-induced carcinoma.(115) In addition, heterozygous loss of SIRT1 accel…”
BackgroundSIRT1 Controls Endothelial Angiogenic Functions During Vascular Growth
Potente, M., Ghaeni, L., Baldessari, D., Mostoslavsky, R., Rossig, L., Dequiedt, F., Haendeler, J., Mione, M., Dejana, E., Alt, F. W., et al. (2007) · Genes & Development · doi:10.1101/gad.435107 · Cited by 608 · cited 1×
“It has been shown that SIRT1 controls endothelial angiogenic functions through deacetylating FOXO1 and Notch1 intracellular domain (NICD) during vascular growth.(108,109) SIRT1 enhances tumor angiogenesis through negatively modulating Delta-like ligand 4 (DLL4)/Notch signaling in Lewis lung carcinoma”
BackgroundThe SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth.
Firestein, R., Blander, G., Michan, S., Oberdoerffer, P., Ogino, S., Campbell, J., Bhimavarapu, A., Luikenhuis, S., de Cabo, R., Fuchs, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002020 · Cited by 588
Metabolism and cancer: the circadian clock connection
Sahar, S., & Sassone-Corsi, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2747 · Cited by 551 · cited 1×
“Considering that cancer is a systematic disease related to disrupted metabolism, SIRT1 may serve as a guard against cancer by providing tight regulation of metabolism in the proper amplitude.(124)”
BackgroundSirT1 Regulates Energy Metabolism and Response to Caloric Restriction in Mice
Boily, G., Seifert, E. L., Bevilacqua, L., He, X. H., Sabourin, G., Estey, C., Moffat, C., Crawford, S., Saliba, S., Jardine, K., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001759 · Cited by 444
SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation.
Vaquero, A., Scher, M., Erdjument-Bromage, H., Tempst, P., Serrano, L., & Reinberg, D. (2007) · Nature · doi:10.1038/nature06268 · Cited by 439 · cited 2×
“SIRT1 also indirectly regulates histone methylation through interacting with other epigenetic enzymes such as methyltransferase SUV39H1.(44) The alteration of histone codes may effectively change the chromatin structure and gene transcription involved in carcinogenesis and cancer drug resistance.”
BackgroundO'Hagan, H. M., Mohammad, H. P., & Baylin, S. B. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000155 · Cited by 386
Nowicki, M. O., Falinski, R., Koptyra, M., Slupianek, A., Stoklosa, T., Gloc, E., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2004) · Blood · doi:10.1182/blood-2004-05-1941 · Cited by 278
SIRT1 Regulates UV-Induced DNA Repair through Deacetylating XPA
Fan, W., & Luo, J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.07.006 · Cited by 223
Gao, Z., Zhang, J., Kheterpal, I., Kennedy, N., Davis, R. J., & Ye, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228874 · Cited by 187 · cited 1×
“SIRT1 phosphorylation at serine 27 by c-Jun N-terminal kinase 2 (JNK2) stabilizes the protein,(33) whereas SIRT1 phosphorylation at serine 47 by JNK1 facilitates ubiquitination-mediated degradation.(34) Under genotoxic stress, nuclear desumoylase SENP1 removes SIRT1 sumoylation and reduces its deacetylase activity.”
BackgroundActivation of Stress Response Gene SIRT1 by BCR-ABL Promotes Leukemogenesis
Yuan, H., Wang, Z., Li, L., Zhang, H., Modi, H., Horne, D., Bhatia, R., & Chen, W. (2012) · Blood · doi:10.1182/blood-2011-06-361691 · Cited by 182
Self-citation
Cited by
Du, Z., Liu, X., Chen, T., Gao, W., Wu, Z., Hu, Z., Wei, D., Gao, C., & Li, Q. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.037 · Cited by 56
Hohman, T. J., Bush, W. S., Jiang, L., Brown-Gentry, K. D., Torstenson, E. S., Dudek, S. M., Mukherjee, S., Naj, A., Kunkle, B. W., Ritchie, M. D., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.031 · Cited by 52
A review on Stimuli-pH responsive liposomal formulation in cancer therapy
Jayapriya, P., Pardhi, E., Vasave, R., Guru, S. K., Madan, J., & Mehra, N. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105172 · Cited by 24
Metadata
- Authors
- Wang, Z., & Chen, W.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2013-01-17
- Volume
- 4
- Issue
- 3-4
- Pages
- 82-90
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- OpenAlex
- W2158742352
- Cited by
- 82
- References
- 42
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.